1. Home
  2. KYTX vs SKLZ Comparison

KYTX vs SKLZ Comparison

Compare KYTX & SKLZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KYTX
  • SKLZ
  • Stock Information
  • Founded
  • KYTX 2018
  • SKLZ 2012
  • Country
  • KYTX United States
  • SKLZ United States
  • Employees
  • KYTX N/A
  • SKLZ N/A
  • Industry
  • KYTX
  • SKLZ EDP Services
  • Sector
  • KYTX
  • SKLZ Technology
  • Exchange
  • KYTX NYSE
  • SKLZ Nasdaq
  • Market Cap
  • KYTX 119.7M
  • SKLZ 106.4M
  • IPO Year
  • KYTX 2024
  • SKLZ N/A
  • Fundamental
  • Price
  • KYTX $4.33
  • SKLZ $8.52
  • Analyst Decision
  • KYTX Strong Buy
  • SKLZ Buy
  • Analyst Count
  • KYTX 5
  • SKLZ 1
  • Target Price
  • KYTX $19.00
  • SKLZ $15.00
  • AVG Volume (30 Days)
  • KYTX 599.4K
  • SKLZ 119.0K
  • Earning Date
  • KYTX 08-11-2025
  • SKLZ 08-04-2025
  • Dividend Yield
  • KYTX N/A
  • SKLZ N/A
  • EPS Growth
  • KYTX N/A
  • SKLZ N/A
  • EPS
  • KYTX N/A
  • SKLZ N/A
  • Revenue
  • KYTX N/A
  • SKLZ $92,644,000.00
  • Revenue This Year
  • KYTX N/A
  • SKLZ $0.20
  • Revenue Next Year
  • KYTX N/A
  • SKLZ $14.10
  • P/E Ratio
  • KYTX N/A
  • SKLZ N/A
  • Revenue Growth
  • KYTX N/A
  • SKLZ N/A
  • 52 Week Low
  • KYTX $1.78
  • SKLZ $3.54
  • 52 Week High
  • KYTX $10.08
  • SKLZ $9.06
  • Technical
  • Relative Strength Index (RSI)
  • KYTX 63.84
  • SKLZ 67.52
  • Support Level
  • KYTX $3.80
  • SKLZ $6.90
  • Resistance Level
  • KYTX $4.39
  • SKLZ $9.06
  • Average True Range (ATR)
  • KYTX 0.39
  • SKLZ 0.42
  • MACD
  • KYTX 0.05
  • SKLZ 0.13
  • Stochastic Oscillator
  • KYTX 93.78
  • SKLZ 76.72

About KYTX KYVERNA THERAPEUTICS INC

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

About SKLZ Skillz Inc.

Skillz Inc is a mobile game development company. It is engaged in re-inventing competitive mobile gaming and thereby expanding the mobile gaming market. Some of the games available on its platform are Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube among others. The company's reportable business segments are; the Skillz segment and the Aarki segment. The majority of its revenue is generated from the Skillz segment which is an eSports gaming platform, enabling game developers to monetize their content through multi-player competition. Geographically, the company derives its key revenue from the United States and the rest from Israel, China, Malta, and other countries.

Share on Social Networks: